NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $88.64 -2.28 (-2.50%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$88.91▼$91.1850-Day Range$82.10▼$90.9252-Week Range$66.66▼$105.47Volume5.60 million shsAverage Volume10.55 million shsMarket Capitalization$4.83 billionAssets Under Management$5.32 billionDividend Yield0.03%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF Overview SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Read More SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.56%0.51%0.53%Other Expenses0.00%0.47%0.56%0.59%0.56%Total Expense0.35%0.75%0.76%0.74%0.73%Fee Waiver0.00%-0.67%-0.66%-0.71%-0.63%Net Expense0.35%0.60%0.63%0.58%0.60% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesInside XBI: What The SPDR S&P Biotech ETF Offers InvestorsAugust 19, 2025 | seekingalpha.comXBI: Surprise Exit Of A Tough Regulator At The FDAJuly 30, 2025 | seekingalpha.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 25 at 2:00 AM | Weiss Ratings (Ad)Biotech stocks dip as Trump administration mulls patent fee overhaulJuly 28, 2025 | finance.yahoo.comSPDR S&P Biotech ETF (XBI) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comXBI Chart | SPDR S&P Biotech ETF - Investing.comJune 25, 2025 | investing.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $90.06 at the start of the year. Since then, XBI stock has decreased by 0.7% and is now trading at $89.4630. Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's top institutional investors include JPMorgan Chase & Co. (19.54%), Jane Street Group LLC, Rubric Capital Management LP and Capital Fund Management S.A.. How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotechnology Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings137 Fund Statistics Assets Under Management$5.32 billion Average Daily Volume$9.91 million Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume67,862 Put Options41,993 Call Options25,869 Short Interest79,500,000 shs Miscellaneous Outstanding Shares54,450,000Beta0.97 Creation Unit50,000 Creation Fee$250.00 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report Top 10 XBI HoldingsAlnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 3.61%Halozyme Therapeutics (NASDAQ:HALO)Holding Weight: 3.06%Insmed (NASDAQ:INSM)Holding Weight: 3.06%Incyte (NASDAQ:INCY)Holding Weight: 2.92%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.67%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 2.60%Gilead Sciences (NASDAQ:GILD)Holding Weight: 2.54%AbbVie (NYSE:ABBV)Holding Weight: 2.53%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 2.52%Biogen (NASDAQ:BIIB)Holding Weight: 2.46%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.